Guardant Health, Inc. 8K

Guardant Health reported strong Q2 2026 revenue growth, raised full-year 2026 revenue guidance, and highlighted key FDA, guideline, and payer milestones for its oncology and Shield screening products while maintaining a sizable but narrowing non-GAAP loss and increasing planned investments and cash burn.

Guardant Health, Inc. filed a Form 8-K to furnish its second quarter 2026 financial results, reporting total revenue of $335.0 million, up 44% year over year, driven by strong growth in oncology testing and a more than 250% increase in screening revenue from its Shield test, while remaining loss-making on both a GAAP and non-GAAP basis. The company highlighted multiple recent milestones, including FDA approval of its Guardant360 Liquid CDx liquid biopsy panel and its use as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2-mutant advanced non-small cell lung cancer, inclusion of the Shield blood test in the American Cancer Society’s updated colorectal cancer screening guidelines, new coverage for Shield from UnitedHealth Group, and FDA approval of a higher-throughput, lower-COGS Shield workflow. Guardant increased its full-year 2026 revenue guidance to $1.34–$1.36 billion (36%–38% growth versus 2025), raised oncology growth expectations and Shield volume and revenue outlook, while also increasing projected 2026 non-GAAP operating expenses and free cash flow burn due to accelerated investment in laboratory capacity to support rapid Shield volume growth, and disclosed continued substantial cash resources of approximately $1.2 billion as of June 30, 2026.

Filing Facts

CIK

1576280

Ticker

GH

Form

8K

Source Type

sec

Accession

0001576280-26-000036

Alert Tier

7